Browse DORAS
Browse Theses
Search
Latest Additions
Creative Commons License
Except where otherwise noted, content on this site is licensed for use under a:

Development of an oral drug delivery platform formulation for the targeted delivery of celecoxib for the chemoprevention and treatment of colorectal cancer.

McDonald, Bernard (2015) Development of an oral drug delivery platform formulation for the targeted delivery of celecoxib for the chemoprevention and treatment of colorectal cancer. PhD thesis, Dublin City University.

Full text available as:

[img]PDF (PhD Thesis - Bernard McDonald) - Archive staff only. This file is embargoed until 12 January 2019 - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
8Mb

Abstract

The anti-inflammatory drug celecoxib (CLX) has been shown to exert protective effects in colorectal cancer (CRC) therapy. The primary objective of this study was to develop and characterize a novel CLX multiparticulate drug delivery technology suitable for use in the treatment and prevention of CRC which has the potential to minimize the side effects associated with CLX. Liquid CLX formulations were developed as precursors to CLX microbeads and the effect of formulated CLX samples on the viability and motility of a CRC cell line was examined. CLX liquid formulations were shown for the first time to have an enhanced effect in comparison to the marketed CLX product Celebrex®. Liquid CLX formulations were translated into an optimized CLX microbead formulation which met a number of pre-defined critical quality attributes. A sustained release coat was applied to the beads. An in-vivo study was performed to compare the effect of the coated CLX microbeads versus Celebrex® in the attenuation of CRC tumours and inflammation in a CRC mouse model. Whilst the level of CRC tumour attenuation and inflammation was comparable between both formulations, the CLX microbead statistically outperformed Celebrex®. Microbead production was scaled-up and subsequent coating optimisation studies were performed resulting in products that met pre-defined target product profiles for both murine and human colon delivery. Finally a screening study to assess the applicability of the platform formulation to a range of APIs other than CLX was performed with 50% of the actives screened being successfully incorporated into microbeads. In summary, the in-vitro and in-vivo results described in this thesis present a significant step forward in CRC therapy using CLX, as the microbead formulation developed poses the possibility of presenting CLX in a format that has the potential to minimize GI and CV side effects whilst enhancing the effectiveness of the treatment.

Item Type:Thesis (PhD)
Date of Award:March 2015
Refereed:No
Additional Information:Dr. Ivan Coulter, Sigmoid Pharma was the external supervisor for this thesis Permission to view this thesis must be emailed to the supervisors: ian.marison@dcu.ie ivan.coulter@sigmoidpharma.com
Supervisor(s):Marison, Ian and Coulter, Ivan
Uncontrolled Keywords:Colorectal cancer; Chemoprevention; Oral drug delivery; Targeted delivery
Subjects:Biological Sciences > Biology
Medical Sciences > Pharmacology
Biological Sciences > Biochemistry
DCU Faculties and Centres:DCU Faculties and Schools > Faculty of Science and Health > School of Biotechnology
Use License:This item is licensed under a Creative Commons Attribution-NonCommercial-No Derivative Works 3.0 License. View License
Funders:Irish Research Council for Science Engineering and Technology, Sigmoid Pharma
ID Code:20409
Deposited On:16 Apr 2015 13:42 by Ian Marison. Last Modified 16 Apr 2015 13:42

Archive Staff Only: edit this record